CBD cream shows promise for chemo nerve pain in small trial

NCT ID NCT05388058

Completed Symptom relief Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a topical cannabidiol (CBD) cream against a placebo cream to see if it could reduce nerve pain, numbness, and tingling in the hands and feet caused by chemotherapy. Forty adults with moderate to severe chemotherapy-induced peripheral neuropathy (CIPN) applied the cream daily for four weeks. The goal was to find a well-tolerated option for a condition that is often hard to treat with standard medications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer chemotherapy-induced neuropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY MALIGNANT SOLID NEOPLASM

Contacts and locations

Locations

Fairview Grand Itasca Clinic and Hospital

Grand Rapids, Minnesota, 55744, United States
Fairview Northland Medical Center

Princeton, Minnesota, 55371, United States
Fairview Range Medical Center

Hibbing, Minnesota, 55746, United States
Mayo Clinic Health System Albert Lea

Albert Lea, Minnesota, 56007, United States
Mayo Clinic Health System Mankato

Mankato, Minnesota, 56001, United States
Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States
Monticello Cancer Center

Monticello, Minnesota, 55362, United States
Sanford Thief River Falls

Thief River Falls, Minnesota, 56701, United States
Sanford Worthington

Worthington, Minnesota, 56187, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.